We’re excited to announce that the first two episodes of the third series of our podcast, “Invent: Life Science”, are now available!
Episode 1: Why Do We Need to Continue Innovating in the CGT Industry?
Explore the importance of harnessing innovation in the Cell and Gene Therapy (CGT) sector. Reflecting on progress in the field, the desire to enable broader patient access highlights concerns over the industry’s capacity to meet future demand. What strategies is the industry considering as we strive to deliver groundbreaking therapies to increasing numbers of patients? Featuring insights from Tay Salimullah of Novartis Gene Therapies and Jason Jones of Cellular Origins.
Episode 2: How Innovation Can Broaden Patient Access
Building on our previous discussion, this episode takes a deep dive into strategies for scaling manufacturing. Discover how considerations of scale enter into early-stage planning, and how to leverage hardware innovation to move the industry forward, broaden access, and facilitate the development of new treatments. Featuring insights from Emma Chan of Orchard Therapeutics and Matt Hewitt of Charles River Laboratories.
Don’t miss these enlightening conversations on the future of CGT and its potential to transform patient care. Tune in now to gain valuable perspectives from industry leaders!
Listen to the new season here
About TTP’s Cell and Gene Therapy Expertise
Cell and gene therapies offer potential cures for some of the most devastating and challenging conditions of our time. With our cell and gene product development expertise, TTP is enabling leading companies to commercialize and realize the full potential of their innovative cell therapies. Find out more here.
About host Stuart Lowe
As Head of the Biotech, Cell and Gene team at TTP, Stuart is passionate about solving time, cost, scale and sustainability challenges in cutting-edge pharmaceutical development, so that more people get access to life-changing therapies, sooner. The work Stuart and his team do enables TTP’s clients to launch disruptive products and create bespoke solutions, opening up new markets.